Noted for their versatility in T2DM management and benefits in heart failure and chronic kidney disease (CKD), SGLT-2 inhibitors were also explored for their anti-cancer qualities, with promising preclinical and clinical findings [17]. Here, SLC5A2 is linked to chronic kidney disease.